NCT03411161View on ClinicalTrials.gov

S 81694 Plus Paclitaxel in Metastatic Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 4, 2018

Primary Completion Date

June 8, 2020

Study Completion Date

June 8, 2020

Conditions
Metastatic Breast CancerMetastatic Triple Negative Breast Cancer
Interventions
DRUG

Combination therapy (S81694 + paclitaxel) phase I

Dose escalation S 81694 (IV); paclitaxel started at 80 mg/m²,(IV)

DRUG

Paclitaxel

Paclitaxel (IV) at 80 mg/m²/week

DRUG

Combination therapy (S81694 + paclitaxel) phase II

S 81694 (IV) at RP2D; paclitaxel (IV) at 80 mg/m²/week

Trial Locations (6)

1000

Institut Jules Bordet Clinique Oncologie Médicale, Brussels

3000

UZ Leuven Campus Gasthuisberg Dept. of General Medical, Leuven

30145

Erasmus MC Section Clinical Pharmacology, Rotterdam

44805

Institut de Cancérologie de l'Ouest site Saint Herblain, Saint-Herblain

2608717

Chiba cancer center Breast surgery, Chiba

5418567

Osaka International Cancer Institute, Osaka

All Listed Sponsors
collaborator

ADIR, a Servier Group company

INDUSTRY

lead

Institut de Recherches Internationales Servier

OTHER

NCT03411161 - S 81694 Plus Paclitaxel in Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter